A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Clinical trial NCT00384228 · COMPLETED

Trial details

NCT number: NCT00384228
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Start date: 2005-05-01
Primary completion: 2007-01-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.